{"filing":{"accession_number":"0001628280-26-059684","cik":"0002007191","ticker":"TLPPF","company_name":"Telix Pharmaceuticals Ltd","form":"6-K","filing_date":"2026-08-31","report_date":"2026-09-01","primary_document":"telix-6kappointmentofdavid.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026059684/telix-6kappointmentofdavid.htm"},"events":[{"id":30723,"run_id":28168,"accession_number":"0001628280-26-059684","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"David Gill has been appointed Chair of the Telix Board effective immediately, succeeding interim Chair Dr. Mark Nelson. The announcement explicitly states \"David Gill has been appointed Chair of the Board, effective immediately\" and describes his extensive background in life sciences leadership and capital markets expertise. This is a material executive appointment to the highest governance position at the company.","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-08-31","form":"6-K","submitted_at":null,"items":[{"id":33417,"accession_number":"0001628280-26-059684","item_number":"EX-99.1","item_title":"davidgillchairappt-nolin.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"David Gill has been appointed Chair of the Telix Board effective immediately, succeeding interim Chair Dr. Mark Nelson. The announcement explicitly states \"David Gill has been appointed Chair of the Board, effective immediately\" and describes his extensive background in life sciences leadership and capital markets expertise. This is a material executive appointment to the highest governance position at the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T10:06:46.506699+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33417,"accession_number":"0001628280-26-059684","item_number":"EX-99.1","item_title":"davidgillchairappt-nolin.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"David Gill has been appointed Chair of the Telix Board effective immediately, succeeding interim Chair Dr. Mark Nelson. The announcement explicitly states \"David Gill has been appointed Chair of the Board, effective immediately\" and describes his extensive background in life sciences leadership and capital markets expertise. This is a material executive appointment to the highest governance position at the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T10:06:46.506699+00:00","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-08-31"}]}